DNA vaccination is a promising cancer treatment due to its safety, but poor immunogenicity limits its application. However, immunoadjuvants, heterogeneous prime-boost strategies and combination with conventional treatments can be used to improve the antitumour immune effects. A CpG motif and interleukin-2 (IL-2) cytokine are often used as adjuvants. In this study, a DNA vaccine containing a CpG motif was constructed to evaluate its adjuvant effect. The results show that the cytotoxicity of the DNA vaccine was increased fivefold, and survival lifetime was prolonged twofold by the CpG motif adjuvant. To simplify the industrial production process, a bicistronic plasmid was constructed to carry the fusion genes of survivin/MUC1 (MS) and IL-2 and with a CpG motif in its backbone. The results showed that the antitumour effect of the bicistronic vaccine was the same as that of the two vaccine co-injected regime. Furthermore, the vaccine could suppress metastatic tumour foci by 69.1% in colorectal carcinoma-bearing mice. Moreover, the vaccine induced survivin-and MUC1-specific immune responses in splenocytes and induced the immune promoting factor CCL-19 and GM-CSF upregulated, while metastatic-associated factor MMP-9 and immunosuppressing factor PD-L1 downregulated in tumour tissue. When combining the vaccine with the chemotherapy drug oxaliplatin, the survival was prolonged by about 2.5-fold. In conclusion, the DNA vaccine containing a CpG motif in bicistronic form showed good effects on colorectal cancer by inhibiting both tumour growth and metastasis, and combination with oxaliplatin could improve its antitumour effects.
Introduction
Many studies have shown that the cellular immune response plays a vital role in eliminating infected cells or tumour cells. Cancer DNA vaccines generally containing a tumour-associated antigen or tumour-specific antigen gene activate the cellular immune response by antigen expressed endogenously [1, 2] . Thus, DNA vaccination is a promising therapeutic approach, especially given its many other advantages, such as good safety profile and stability during storage and transport [3] . After years of effort, many DNA vaccines have advanced into clinical trials (e.g. ClinicalTrials.gov identifier: NCT00062907, NCT01493154, NCT00199849). Although most of them demonstrated a sufficient safety profile during phase I clinical trials, many unfortunately lacked good immunogenicity in subsequent research [4] . Recently, many methods to enhance immunogenicity, such as immune adjuvants, heterogeneous primeboost strategies and combinations with chemotherapy drugs, have been tested in preclinical and clinical trials [5] [6] [7] . Therefore, to develop an effective DNA vaccine, it is necessary to use the above methods in addition to selecting the ideal tumour antigen.
Tumour antigens survivin and MUC1 are both reported to be upregulated and associated with the recurrence, metastasis and drug resistance in many cancers [8] [9] [10] . In our previous research, survivin and MUC1 showed a better antitumour effect when combined in a vaccine than when given separately in a murine melanoma model [11] . Hence, we chose survivin and MUC1 as the targets of immunotherapy aimed at different cancers. Colorectal cancer (CRC) is the second leading cause of cancer-related deaths [12] . Recurrence and metastasis are key challenges in the treatment of CRC. In this study, we investigated the antitumour effect of a gene vaccine targeting survivin and MUC1 in a murine CRC model.
To enhance the immunogenicity in many DNA vaccine studies, immune adjuvants such as dinucleotide motifs and cytokines have been widely used [13] . The CpG motif, a series of unmethylated CG dinucleotides with flanking regions, has been often included in vaccines to enhance the immunogenicity and applied in clinical trials [14, 15] . Three types of CpG motifs have been described. CpG-A tends to induce a cellular immune response, while CpG-B more easily activates B cells to induce humoral immunity. Hartmann et al. [16] identified the C type of CpG which can induce both cellular immunity and humoral immunity. As an adjuvant, CpG is ideally matched with DNA vaccines, because the nucleotide sequence can be constructed into the backbone of the plasmid DNA vaccine instead of needing to be administered as a separated agent.
Interleukin-2 (IL-2) is a major cytokine used as an immune modulator with various immunotherapies [17] . With the strong ability to activate lymphocytes, IL-2 has been approved for the treatment of metastatic renal cell carcinoma and metastatic melanoma [18, 19] . Our previous study showed that adding IL-2 to our DNA vaccine could strongly enhance the antitumour effects [11] .Besides adjuvants, the heterogeneous prime-boost immune strategy, which entails immunizing different forms of vaccines in sequence, is a classical method for enhancing the immune response [20] [21] [22] . The strategy of DNA vaccine prime-virus vaccine boost is increasingly being applied in clinical trials (e.g. ClinicalTrials.gov identifier: NCT00062907, NCT00472719) and preclinical studies [23, 24] . Our own research also found that the DNA vaccine prime-adenovirus vaccine boost strategy was better than that of repeated immunization with a single type of vaccine [11] . Data in this research were all based on the heterogeneous prime-boost immune strategy, and antitumour effects of two types of DNA vaccines with the same rAd boost were compared. In clinical practice, cancer vaccines, as with other immunotherapies, are always used together with the conventional treatment including chemotherapy and radiotherapy [25, 26] . When an immune therapy is combined with chemotherapy, outcomes differ depending on the chemotherapeutic agents and metronomic chemotherapy [27] [28] [29] . Oxaliplatin is one of the most effective and popular agents used in the treatment of colorectal cancer [30] . Some reports have suggested that oxaliplatin could enhance the sensitivity to PD-1 immune therapy [31] and induce immunogenetic cell death (ICD) [32, 33] . Therefore, in this study, oxaliplatin was administered along with the vaccine to enhance effects of the immunization. In our previous study, two tumourassociated antigens, survivin and MUC1, were chosen as the immunogens, and their fusion DNA vaccine (VR-MS) and recombinant type-5 adenovirus vaccine (Ad-MS) were constructed [22] . In addition, an IL-2-expressing plasmid (VR-IL2) was also constructed and used as an immunoadjuvant. Moreover, using a DNA prime-rAd boost immune strategy was shown to significantly inhibit the melanoma tumour growth in tumour-bearing mice [11, 22] .
In this study, to further enhance the antitumour effects of our survivin-and MUC1-based DNA vaccine, a CpG motif was added into the DNA vector backbone. Meanwhile, to simplify procedures and reduce costs in future industrial production, a bicistronic expression vector containing a CpG motif, IL-2 adjuvant and survivin and MUC1 fusion antigens, CpDV-IL2-MS, was constructed.
The aims of this study were to determine whether (1) the CpG adjuvant could improve the immune response and antitumour effect, (2) the DNA vaccine CpDV-IL2-MS could show equal efficacy as compared to the CpVR-MS and VR-IL2 combination, (3) combination of the promising gene vaccine CpDV-IL2-MS and the traditional chemotherapy drug oxaliplatin would prolong survival and suppress tumour progression in a mouse model.
Materials and methods
Construction of plasmids CpVR-MS and CpDV-IL2-MS. The plasmids VR-MS [expressing a fusion gene of human truncated survivin S8 and human 33 MUC1 VNTRs (MS)] and VR-IL2 (expressing human IL-2) were constructed previously [11] and used to generate CpVR-MS and CpDV-IL2-MS. C-type core CpG motif 5 0 -TCGTCGTC GTTCGAACGACGTTGAT-3 0 [16] was synthesized and cloned into the SalI and XhoI sites of the pBluescriptIISK (+) vector. The resultant vector pBluescriptIISK(+)-CpG (Sangon Biotech (Shang Hai) Co., Ltd.) was obtained, and the core motif has been described by Hartmann et al. [16] . The number of CpG motifs affects immune regulation. Hence, to increase the number of CpG motifs, the plasmid pBluescriptIISK(+)-CpG was digested with SalI/XhoI or XhoI. The CpG fragment digested by SalI/XhoI was inserted back into pBluescriptIISK (+)-CpG at the XhoI site, resulting in pBluescriptIISK-(+)-2CpG. The plasmid pBluescriptIISK-(+)-2CpG was then used to repeat this procedure, resulting in pBluescriptIISK(+)-4CpG. Finally, the CpG motif was then cut and inserted into VR-MS at the StuI site to construct CpVR-MS. In total, there are 13 CpG core motifs in CpVR-MS and CpDV-IL2-MS.
To obtain a double-cassette vector, the plasmid VR1012 was used as the backbone, and its regulatory elements biosynthetic growth hormone poly A (BGH), cytomegalovirus promoter (CMV) and intron A sequences were inserted into VR1012. BGH and CMV-intronA were obtained by polymerase chain reaction (PCR) and cloned into VR1012 at its polyclonal restriction site using the following primers: BGH forward, 5
The plasmid VR1012 was used as the template. The BGH and CMV-intronA fragments were inserted into pGEM-T-easy at the BglII or BamHI sites, separately, and pGEM-BGH and pGEM-CMV-intronA were obtained. The plasmids pGEM-BGH and pGEM-CMV-intronA were subcloned into VR1012, which inserted two cassettes, and the resulting plasmid vector was called DV. Four CpG motifs were then subcloned into StuI of the DV plasmid, and the CpDV vector was obtained. The fragment IL-2 from VR-IL2 was then subcloned into CpDV at the restriction enzyme site BamHI, and the plasmid CpDV-IL2 was obtained. Thereafter, the MS fragment from VR-MS was inserted at the BglII site of CpDV-IL2, finally resulting in CpDV-IL2-MS. CpVR-MS and CpDV-IL2-MS were sequenced to identify the inserted fragments. The expression levels of survivin, MUCI and IL-2 were detected by Western blot using a rabbit anti-human survivin polyclonal antibody (NovusBiologicals), mouse anti-human MUC1 monoclonal antibody (BD Pharmingen) and mouse anti-human IL-2 monoclonal antibody (Abcam). Purification of the plasmids and recombinant adenovirus AD-MS was carried out as described previously [11] .
MS + CT26 stable cell line. The previously constructed plasmid pEGFP-MS was transfected into CT26 cells [22] , which were then cultured with G418 (final concentration: 600 lg/ml). When the percentage of MS-positive transfected cells was about 60%, the cells were separated by flow cytometry, and single-positive cells were obtained and cultured. Finally, the MS + CT26 stable cell line was obtained with the positive ratio of 98%.
Mice and murine tumour model. Mice. As the source of murine tumour colorectal cells CT26 (National Engineering Laboratory for AIDS Vaccine of Jilin University), BABL/c mice were used in immunogenicity and antitumour assays. Female BALB/c at the age of 6-8 weeks were purchased from Beijing Huafukang Biology Technology Co. Ltd. and kept in a specific pathogen-free (SPF) environment. All animal procedures were conducted following the Guide for the Care and Use of Laboratory Animals (National Research Council).
Mouse tumour model. To obtain a model of carcinoma in situ, BALB/c mice (ten per group) were injected with 1 9 10 6 MS + CT26 cells subcutaneously on the right back. When the tumour mass was palpable, the major axis (a) and minor axis (b) were measured using a vernier caliper. The tumour volume was calculated by the formula: 0.5 ab 2 (mm 3 ). In the tumour metastatic model, BALB/c mice (four per group) were injected with 2 9 10 5 MS + CT26 cells intravenously. To measure the metastatic foci, the lung tissue was dissected, and the foci were counted under a microscope. Immunization regimens. In immunogenicity assays, BALB/c mice (five per group) were immunized with plasmids (100 lg) twice and Ad-MS (1 9 10 8 pfu) once intramuscularly into the skeletal muscle of both hindlimbs on days 1, 15 and 29.
In antitumour assays, BALB/c mice (ten per group) were injected with MS + CT26 cells subcutaneously or intravenously on day 0, and immunized with plasmids twice and Ad-MS once at the same dosage and administration route on days 1, 8 and 15. BALB/c mice were intraperitoneally injected with oxaliplatin (dosage: 5 mg/kg) four times on days 6, 10, 14 and 18.
Cytotoxicity assay. In vitro cytotoxicity activity of vaccinated mice was detected through a lactate dehydrogenase (LDH) release assay as previously described [11, 22, 34] . Briefly, splenocytes from the vaccinated mice were mixed at different effector to target (E:T) ratios with 1 9 10 4 CT26 or MS + CT26 cells for 4 h. CTL activity was evaluated by analysing the released LDH [11, 22, 34] .
IFN-c ELISPOT assay. Lymphocytes were incubated with H-2 D b -restricted peptides, hMUC1 peptide (APDTRPAPG) and hSurvivin peptide (AFLSVKKQF) in an Elispot plate. The release of IFN-c was detected using an ELISPOT kit (BD Biosciences), and the procedure was carried out according to the instructions as described previously [11, 34] .
Quantitative real-time PCR (qRT-PCR). The mRNA was isolated from the tumour tissue with TRIzol reagent (Invitrogen, USA) and used to synthesize cDNA using the PrimeScript TM RT reagent Kit with gDNA Eraser (TaKaRa, Dalian, China). The mRNA levels of different target genes were detected by qRT-PCR performed in the CFX96 real-time PCR detection system (Bio-Rad, USA) using SYBR â Premix Ex Taq TM Tli RNaseH Plus (TaKaRa) according to the manufacturer's instructions. The detected transcripts encoded chemokines (CCL-3, CCL-4, CCL-5, CCL-19, CCL-20 and CCL-21), cytokines (IL-2, IFN-c, TNF-a and GM-CSF) and immune modulating factors in the tumour microenvironment (VEG-F, SDF-1, FAP, MMP-9, IL-10 and PDL-1). Primers and other details have been described in previously published reports by our group [11, 34] and others [35] [36] [37] . qRT-PCR data were analysed using the comparative Ct method, and expression levels of target genes were normalized to b-actin levels in each tissue sample.
Statistical analysis. Statistical analyses for the survival experiment were performed with SPSS software, and others Ó 2017 The Foundation for the Scandinavian Journal of Immunology were performed by t tests (and non-parametric test) with GraphPad Prism software. In all the statistical methods, values of P < 0.05 were considered significant, and those of P < 0.01 were highly significant.
Results

Construction of DNA vaccines
DNA vaccines CpVR-MS and CpDV-IL2-MS were constructed as described in methods (Construction of plasmids CpVR-MS and CpDV-IL2-MS) (Fig. 1A) and confirmed to be correct based on restriction enzyme digestion (Fig. 1B) and Western blotting with antibodies against survivin, MUC1 and IL-2 (Fig. 1C) . IL2 and the fusion protein of survivin and MUC1 were expressed from two separate cassettes. The IL-2 gene was inserted into the cassette which expressed the protein at a lower level (data not shown).
CpG motif enhances immune responses and antitumour effects
Enhancements of antitumour effects and immune responses by the CpG motif were evaluated. BABL/c mice were immunized with or without the CpG vaccine CpVR-MS or VR-MS, along with the immunoadjuvant VR-IL2 (abbreviated as CpMS+IL2 and MS+IL2) as described in methods (Immunization regimens) ( Fig. 2A) . In terms of humoral immunity, CpMS+IL2 group stimulated a higher antibody level than MS+IL2 group (Fig. 2B) in the serum. The cellular response also was detected using Elispot and CTL assays. By adding the CpG motif, the Elispot results indicated that the IFN-c-secreting splenocytes were increased by 69.23% and 29.07% in lymphocytes stimulated with MUC1 peptide (P < 0.01) and survivin peptide (P < 0.01), respectively (Fig. 2C) . CD8 + T cells are the main killer cells in splenocytes. To compare the cytotoxicity, splenocytes were separated and applied in CTL assays. The data showed that the specific lysis in the CpMS+IL2 group was increased by almost fivefold (from 6.71% to 35.11% at the E:T ratio of 50:1 and from 13.05% to 74.67% at the E:T ratio of 100:1) compared with that of the MS+IL2 group (Fig. 2D) .
The in vivo antitumour effect of the DNA vaccine with added CpG motif was also evaluated by measuring survival rates. On day 37 after tumour challenge, mice treated with PBS were all died; meanwhile, the survival rate of mice treated with CpMS+IL2 was 70% and that of the MS+IL2 group was 30% (Fig. 2E) . The survival period was prolonged to 26.67% in the CpMS+IL2 group compared with 13.33% in the MS+IL2 group, which indicated an increase in twofold by the CpG motif.
These evaluations of immune responses and antitumour effects indicated that inserting the CpG motif into the DNA vector backbone worked well to enhance immunogenicity, and CpVR-MS was demonstrated to be a more effective DNA vaccine than VR-MS.
Bicistronic expression DNA vaccine vector CpDV-IL2-MS shows equivalent antitumour effects compared with CpVR-MS and VR-IL2 combination
Based on the excellent antitumour effects observed with CpVR-MS combined with VR-IL2, a bicistronic expression vector designated as CpDV-IL2-MS was constructed, which contained the genes of survivin and MUC1 (MS), immune adjuvant IL-2 and CpG motif. If proven feasible, this strategy of expressing both the immunogen and the immunoadjuvants from the same vector would simplify procedures and costs in future clinical applications. Therefore, the abilities to induce immune responses and suppress tumour growth of CpDV-IL2-MS and CpMS+IL2 were compared. The CTL assay results showed that specific cytolysis of the CpDV-IL2-MS group was 21.47%, while that of the CpMS/IL2 group was 25.87% (E:T ratio of 100:1), but no significant difference between them was detected (P > 0.05) (Fig. 3A) . Moreover, IFN-c-secreted splenocytes in the CpDV-IL2-MS and CpMS+IL2 groups were evaluated by Elispot assays (Fig. 3B) . The percentage of IFN-c spots was reduced by 15.71% when the splenocytes were stimulated with the survivin peptide, and it was increased by 13.59% when stimulated with the MUC1 peptide in the CpDV-IL2-MS group compared with the CpMS+IL2 group. The immune response elicited by CpDV-IL2-MS only slightly declined. To explore whether the small decline would affect the antitumour effect, tumour-bearing mice were vaccinated with CpDV-IL2-MS or CpMS/IL2 and boosted with rAd (Fig. 3C,D) . In the antitumour experiment, 28 days after tumour challenge, both DNA vaccines significantly suppressed the tumour mass growth compared with the PBS treatment (P < 0.01).
After sacrifice, the tumour mass was removed and weighed. Surprisingly, the in vivo antitumour effect of the CpDV-IL2-MS group was only slightly better than that of the CpMS/IL2 group. However, the antitumour effects between these two groups were not statistically significantly different, with the tumour inhibition rates of the CpDV-IL2-MS and CpMS+IL2 groups being 41.01% and 36.24%, respectively. This finding suggests that the slight decline in immune response of the CpDV-IL2-MS vaccine compared with the CpMS+IL2 vaccine did not affect the antitumour response. Hence, CpDV-IL2-MS would be a more ideal DNA vaccine than CpVR-MS/IL-2 due to its equivalent antitumour effects and simplicity in industrial production.
CpDV-IL2-MS is an effective treatment vaccine in mouse tumour metastasis model
According to the hallmarks of cancer proposed by Hanahan and Weinberg, activating invasion and metastasis are the characteristics of malignant tumours [38] , which leads to a poor prognosis after surgery, radiotherapy and chemotherapy. As described above, CpDV-IL2-MS was demonstrated to be an ideal candidate for its effectiveness and convenience. We therefore wondered whether CpDV-IL2-MS could impose restrictions on the metastatic tumour foci. As shown in Fig. 4A , 27 days after the intravenous tumour challenge, all mice were sacrificed, and their lungs were dissected to examine the metastatic foci (Fig. 4B) . Metastatic foci in the vaccine group were reduced by 69.14% compared with the PBS group (P < 0.01) (Fig. 4C) . Results of the CTL assay showed that the vaccine induced about a twofold higher level of cytolytic activity compared with the PBS group (Fig. 4D) . These results indicated that abundant cytolytic immune cells were induced by the CpDV-IL2-MS vaccine to reduce the tumour cells forming the metastatic tumour foci.
Development of a metastatic tumour is a complex process in which many immune factors take part. To investigate which factor may participate in the antitumour metastatic activity of the vaccine, several chemokines, cytokines and tumour microenvironment factors were detected in the tumour mass by qRT-PCR. The chemokine-encoding transcripts CCL-3, CCL-4, CCL-5, CCL-19, CCL-20 and CCL-21 were detected. As shown in Fig. 4E , CCL-19 was upregulated clearly, while the other chemokine transcripts were only modestly changed or even not at all. The cytokine transcripts tested included IL-2, IFN-c, TNF-a and GM-CSF. Among them, GM-CSF was found to be increased by about three times compared with the PBS group (Fig. 4F) . Other factors derived from tumour cells and tumour stromal cells, which play an important role in forming the microenvironment or suppressing functional immune cells, were examined including VEG-F, SDF-1, FAP, MMP-9, IL-10 and PDL-1. Among them, MMP-9 and PDL-1 were significantly reduced by the CpDV-IL2-MS vaccine. Hence, the CpDV-IL2-MS vaccine protected mice from tumour metastasis by regulating several types of immune factors. Therefore, CpDV-IL2-MS could control the formation and growth of tumours in the mouse model.
Combination of vaccine and oxaliplatin improves antitumour effects
CpDV-IL2-MS showed good antitumour effects in terms of tumour growth or number of metastatic foci. We next investigated whether it could be combined with chemotherapy or serve as an alternative therapeutic regimen in future clinical treatment of cancer patients. CpDV-IL2-MS (abbreviated as vaccine) and the chemotherapy drug oxaliplatin were used together in the combination group (vaccine + oxa group) (Fig. 5A) . Antitumour effects and immune responses were analysed. When the tumour was detectable, tumour size was measured every other day. Mice were sacrificed on the 22nd day, when the tumour mass was dissected, and splenocytes were analysed in CTL assays. The tumour inhibition rates of the vaccine group and oxa group were 29.63% (P < 0.05) and 62.78% (P < 0.001), respectively, while that of the combined group (vaccine + oxa) was 67.7% (P < 0.001) (Fig. 5B) .
In the clinical treatment of cancer patients, the survival period is another important parameter. Thus, the survival time of the four groups was observed in this study. At 57 days after tumour challenge, all mice in the PBS group had died, while the survival rates were 30%, 40% and 30% in the vaccine, vaccine + oxa and oxa groups, respectively. In each of the vaccine + oxa and oxa groups, three mice died due to the toxicity of oxaliplatin. The observations continued until all of the mice died. Compared with the PBS group, the rates of prolonged survival of the vaccine, vaccine + oxa and oxa groups were 22.83% (P < 0.05), 56.52%(P < 0.01) and 15.22% (P < 0.05), respectively (Fig. 5C) . Especially, vaccine+oxa group prolonged the lifetime rate compared with both vaccine (P < 0.05) and oxa (P < 0.05) groups significantly. Although combining the vaccine with the chemotherapy agent oxaliplatin (vaccine + oxa group) did not show a vast improvement in controlling tumour growth, a noteworthy synergistic effect in extending the lifetime of tumour-bearing mice was observed.
Discussion
The DNA vaccine, CpDV-IL2-MS, composed of a survivin and MUC1 fusion gene and immunoadjuvants CpG motif and IL-2, was constructed and analysed in this study. Our results indicated that the CpG motif could enhance the antitumour effects of the vaccine, and the bicistronic construct CpDV-IL2-MS was determined to be a suitable and more convenient form of DNA vaccine than using CpVR-MS and VR-IL2. Moreover, CpDV-IL2-MS could effectively suppress the growth and metastatic foci of tumours in vivo. Increasingly, DNA vaccines have entered clinical trials and showed good safety but poor immunogenicity. Thus, combining a DNA vaccine with an immunoadjuvant is necessary. CpG motifs and IL-2 are also widely used as adjuvants in clinical trials [39] [40] [41] . IL-2 was first approved in the treatment of metastatic renal cancer patients by the FDA.
In our study, two adjuvants, CpG motif and IL-2, were constructed into the plasmid DNA vaccine CpDV-IL2-MS to enhance the antitumour effect. The CpG motif is reported as a toll-like receptor 9 (TLR9) agonist. TLR9 is always expressed on the surface of B cells and plasmacytoid DCs (pDCs), which are involved in antigen presentation [13] . The CpG motif included in the vaccine in this study could enhance both humoral immunity and cellular 5 MS + CT26 through the tail vein. In the next 14 days, the mice were vaccinated with DNA or Ad-MS three times at 7-day intervals. On the 22nd day, the mice were sacrificed, lung tissues were dissected (B), and numbers of metastatic foci were observed (C). Splenocytes were incubated with MS + CT26 cells at E:T ratios of 25:1, 50:1 and 100:1 in CTL assays (D). (E-H) mRNA levels of chemokines, cytokines and immune regulatory factors. CCL-19 (E) and GM-CSF (F) were upregulated; MMP-9 (G) and PDL-1 (H) were downregulated in metastatic lung tumour tissues. Results are presented as the mean AE SD (*P < 0.05, **P < 0.01). ............................................................................................................................................................... immunity (Fig. 2) . The other adjuvant IL-2, which is an important T helper type 1 (Th1) cytokine, plays an important role in activating lymphocytes, as we have demonstrated in our previous research [11] .
CpDV-IL2-MS is constructed based on CpDV, which is a bicistronic expression vector in which each cassette differs in expression efficiency. To induce a high level of survivinand MUC1-specific immune response, the IL-2 was placed in the cassette with the lower expression efficiency, while the survivin and MUC 1 fusion gene encoding the immunogen was placed in the higher one. Importantly, no side effects were found in this study. DNA vaccines are much safer, more stable and more easily manufactured than virus-vectored vaccines.
CpDV-IL2-MS as a single component would have the advantage in an industrial manufacturing process compared with the production of CpVR-MS and VR-IL2 separately. In analysing the cellular immune response after vaccination, CpDV-IL2-MS showed slightly lower antigen-specific IFN-c secretion and cytolysis. We considered that the phenomenon may be caused by the lower copy number of antigen genes. Although these vaccines were given at the same amount (100 lg) each time, the plasmid size of CpDV-IL2-MS (11,136 bp) is much larger than that of CpVR-MS (7910 bp). Therefore, fewer copies of the CpDV-IL2-MS vector were given in each inoculation. Interestingly, CpDV-IL2-MS yielded equivalent antitumour effects even while showing a weaker immune response compared with CpVR-MS/VR-IL2. Additionally, CpDV-IL2-MS was also effective in the treatment of metastatic tumours.
As eliciting a strong immune response with a simple DNA vaccine is difficult, in addition to the use of CpG motif and IL-2 immunoadjuvants, a heterogeneous primeboost immunization strategy was also used. In our previous research, a recombinant adenovirus (rAd) vaccine containing MS fusion gene was described, and the rAd could boost the immune response following DNA vaccination [11] . In this research, mice were boosted with the rAd vaccine following twice DNA vaccinations to induce a better immune response. Using this prime-boost immunization strategy, the immune response and antitumour effects of 
